<code id='AEB0F6203F'></code><style id='AEB0F6203F'></style>
    • <acronym id='AEB0F6203F'></acronym>
      <center id='AEB0F6203F'><center id='AEB0F6203F'><tfoot id='AEB0F6203F'></tfoot></center><abbr id='AEB0F6203F'><dir id='AEB0F6203F'><tfoot id='AEB0F6203F'></tfoot><noframes id='AEB0F6203F'>

    • <optgroup id='AEB0F6203F'><strike id='AEB0F6203F'><sup id='AEB0F6203F'></sup></strike><code id='AEB0F6203F'></code></optgroup>
        1. <b id='AEB0F6203F'><label id='AEB0F6203F'><select id='AEB0F6203F'><dt id='AEB0F6203F'><span id='AEB0F6203F'></span></dt></select></label></b><u id='AEB0F6203F'></u>
          <i id='AEB0F6203F'><strike id='AEB0F6203F'><tt id='AEB0F6203F'><pre id='AEB0F6203F'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:entertainment    - browse:99778

          Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

          Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

          advertisement

          You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time